[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-001", "question": "A 54-year-old man with decompensated alcoholic cirrhosis (MELD-Na 29) is intubated for acute variceal hemorrhage and started on norepinephrine for hemorrhagic shock. Despite volume resuscitation, blood products, and endoscopic band ligation, he requires increasing vasopressor doses. Continuous renal replacement therapy is initiated for worsening azotemia and hyperkalemia. His MAP is 62 mm Hg on norepinephrine 0.24 mcg/kg/min and vasopressin 0.03 units/min. Lactate is 5.1 mmol/L; pH 7.28; ScvO2 76%. Bedside echo shows hyperdynamic LV function, small underfilled LV, and collapsible IVC. CVP is 4 mm Hg. You are considering adding a third agent. Which vasopressor strategy is most appropriate now?", "options": ["Add epinephrine infusion targeting higher MAP (70-75 mm Hg)", "Add low-dose dobutamine to improve splanchnic perfusion", "Add angiotensin II infusion while maintaining current MAP target", "Increase vasopressin above 0.04 units/min to exploit V1 receptor effect", "Switch norepinephrine to phenylephrine to minimize beta-adrenergic effects"], "answer": "C", "answer_index": 2, "explanation": "He has vasodilatory shock in advanced cirrhosis with catecholamine-resistant hypotension despite adequate volume; angiotensin II is reasonable as a third-line agent in catecholamine-refractory vasodilatory shock and has emerging use in hepatorenal-type circulatory failure. Epinephrine would increase lactate and myocardial oxygen demand without addressing RAAS dysregulation; high-dose vasopressin increases ischemia risk, phenylephrine may worsen gut perfusion, and dobutamine is not indicated with hyperdynamic LV and adequate ScvO2.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient has decompensated cirrhosis with variceal bleeding, shock, and acute kidney injury requiring CRRT.  \nDespite norepinephrine and vasopressin, he remains hypotensive with signs of persistent hypoperfusion (elevated lactate, metabolic acidosis).  \nThe echo shows a hyperdynamic, underfilled left ventricle and a collapsible IVC with low CVP, suggesting that the primary problem is distributive/vasodilatory shock (likely from cirrhosis and sepsis) with possible relative hypovolemia, but he is already on vasopressors.  \n\n- **A** – Epinephrine would increase cardiac output and vasoconstriction but can worsen splanchnic ischemia and lactate; in cirrhosis, epinephrine may increase portal pressure and risk rebleeding.  \n- **B** – Dobutamine is an inotrope; the echo already shows hyperdynamic LV, so increasing contractility is not needed and could worsen vasodilation and hypotension.  \n- **C** – Angiotensin II targets the RAAS pathway, causing vasoconstriction, and has been used in vasodilatory shock with norepinephrine resistance. In cirrhosis, angiotensin II may help increase MAP without increasing portal pressure as much as other agents, and it may improve renal perfusion in hepatorenal syndrome physiology. This is a reasonable third agent.  \n- **D** – Increasing vasopressin above 0.04 units/min increases risk of ischemic complications; usual max in septic shock is 0.03–0.04 units/min.  \n- **E** – Phenylephrine is a pure alpha-agonist; switching from norepinephrine would remove beta-1 support, potentially reducing cardiac output, and is generally less effective in distributive shock.  \n\nGiven the scenario of cirrhosis, vasodilatory shock, and need for a third vasopressor, angiotensin II is a reasonable evidence-based option to improve MAP without worsening portal hypertension or splanchnic ischemia excessively.  \n\nThe answer is C"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-002", "question": "A 63-year-old woman with a history of JAK2-positive polycythemia vera treated with hydroxyurea for 9 years presents with 3 months of progressive fatigue, 7-kg weight loss, early satiety, and drenching night sweats. Exam shows marked splenomegaly 12 cm below the costal margin. CBC: Hgb 9.1 g/dL, MCV 96 fL, WBC 18,000/µL with left shift, platelets 110,000/µL. Peripheral smear reveals tear-drop cells, nucleated RBCs, and leukoerythroblastosis. LDH is elevated; uric acid is high. Bone marrow aspirate is 'dry'; core biopsy shows hypercellular marrow with grade 3 reticulin fibrosis and atypical megakaryocytic clusters. Cytogenetics: new complex karyotype with monosomy 7. Which is the most appropriate next step in disease-directed management?", "options": ["Escalate hydroxyurea dose and add low-dose aspirin", "Start ruxolitinib and defer further planning until spleen size stabilizes", "Proceed to allogeneic hematopoietic stem cell transplantation evaluation", "Begin azacitidine as first-line therapy for post-PV myelofibrosis", "Initiate weekly pegylated interferon alfa-2a for cytoreduction"], "answer": "C", "answer_index": 2, "explanation": "She has post-polycythemia vera myelofibrosis with symptomatic splenomegaly, cytopenias, leukoerythroblastosis, and high-risk features (complex karyotype, monosomy 7), making allogeneic stem cell transplantation the only curative option and the preferred strategy if eligible. Ruxolitinib improves symptoms and spleen size but is not curative; azacitidine and interferon are not standard first-line disease-modifying therapies in high-risk post-PV MF, and hydroxyurea escalation will not address progression.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient with polycythemia vera (PV) has progressed to post-PV myelofibrosis with high-risk features:  \n- Symptomatic progressive disease (fatigue, weight loss, night sweats)  \n- Marked splenomegaly  \n- Leukocytosis, anemia, thrombocytopenia  \n- Leukoerythroblastic smear  \n- High-risk cytogenetics (monosomy 7)  \n- Bone marrow fibrosis grade 3  \n\nIn myelofibrosis, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only potentially curative option and is considered for higher-risk patients. Given her age (63), performance status likely acceptable, and high-risk features, proceeding to transplant evaluation is appropriate.  \n\nRuxolitinib (B) is used for symptomatic splenomegaly or constitutional symptoms but is not curative and does not alter disease progression significantly in high-risk patients without transplant.  \nAzacitidine (D) is not standard first-line for myelofibrosis.  \nEscalating hydroxyurea (A) or starting interferon (E) would not address the high-risk transformation.  \n\nThe answer is C"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-003", "question": "A 28-year-old G1P0 woman at 33 weeks' gestation presents to the ED with acute dyspnea, pleuritic chest pain, and near syncope. HR 132/min, BP 82/48 mm Hg, RR 30/min, SpO2 89% on 6 L nasal cannula. Bedside echo reveals a dilated RV with McConnell sign and septal flattening. CTA is unavailable; lower-extremity duplex is pending. She is consentable and has no contraindications to thrombolysis. Fetal heart tones are 150 bpm with moderate variability. Which management is most appropriate now?", "options": ["Systemic thrombolysis with weight-based alteplase bolus and infusion", "Urgent catheter-directed thrombolysis with reduced-dose alteplase", "Immediate transfer for surgical embolectomy with cardiopulmonary bypass", "Initiate high-dose unfractionated heparin and defer reperfusion until postpartum", "Administer tenecteplase as a single IV bolus followed by heparin"], "answer": "A", "answer_index": 0, "explanation": "She has high-risk (massive) pulmonary embolism with shock in late pregnancy; systemic thrombolysis is recommended when no absolute contraindications exist, as maternal survival takes priority and pregnancy is only a relative contraindication. Catheter-directed therapy or surgical embolectomy may be considered when thrombolysis is contraindicated or fails, not as first-line; deferring reperfusion is unsafe, and tenecteplase bolus lacks robust pregnancy-specific safety and dosing data compared with standard alteplase protocols.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient has signs of massive pulmonary embolism (hypotension, tachycardia, hypoxemia, RV dysfunction on echo) in the third trimester of pregnancy. In massive PE with hemodynamic compromise, systemic thrombolysis is indicated if no major contraindications exist. Pregnancy is not an absolute contraindication to thrombolytics, and alteplase does not cross the placenta in significant amounts. Given her instability and consentability, immediate systemic thrombolysis is appropriate.  \n\nCatheter-directed thrombolysis (B) may be considered but is less appropriate as first-line in an unstable patient when systemic thrombolysis is available and faster to initiate. Surgical embolectomy (C) is reserved for when thrombolysis is contraindicated or failed. Heparin alone (D) is insufficient in massive PE with shock. Tenecteplase (E) is not FDA-approved for PE in pregnancy and less studied than alteplase in this setting.  \n\nThe answer is A"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-004", "question": "A 4-year-old boy is brought to the PICU with progressive leg weakness and refusal to walk for 5 days after a viral upper respiratory infection. Exam: flaccid symmetric weakness in legs > arms, areflexia, intact sensation, no bowel/bladder dysfunction, and no cranial nerve involvement. He can lift his head briefly but cannot stand; FVC is 55% predicted. MRI spine is normal. CSF shows protein 42 mg/dL, 3 WBC/µL. Nerve conduction studies show reduced CMAP amplitudes with preserved conduction velocities and distal latencies; sensory studies are normal, and F-waves are absent. Which subtype best describes his neuropathy and has implications for prognosis and treatment response?", "options": ["Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)", "Acute motor axonal neuropathy (AMAN) variant of Guillain-Barré syndrome", "Acute motor and sensory axonal neuropathy (AMSAN)", "Miller Fisher syndrome", "Acute flaccid myelitis related to enterovirus D68"], "answer": "B", "answer_index": 1, "explanation": "Normal conduction velocities with low CMAP amplitudes, preserved sensory responses, and absent F-waves indicate a purely motor axonal process, characteristic of AMAN, which in children often follows infection and may have rapid progression but good recovery with immunotherapy. AIDP would show demyelinating features (slowed velocities, prolonged latencies), AMSAN would have sensory involvement, Miller Fisher presents with ophthalmoplegia/ataxia, and acute flaccid myelitis involves spinal gray matter with MRI abnormalities and asymmetric weakness.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The clinical picture is Guillain-Barré syndrome (GBS) with acute flaccid paralysis, areflexia, antecedent infection, CSF albuminocytologic dissociation, and electrodiagnostic findings of reduced CMAP amplitudes (axonal pattern) with normal sensory studies and absent F-waves.  \n\nThe key features pointing away from AIDP are the preserved conduction velocities and distal latencies (demyelination typically shows slowed conduction and prolonged latencies), and normal sensory studies. The pattern fits an axonal GBS subtype.  \n\nSince the weakness is motor-only with intact sensation and normal sensory nerve studies, this matches **acute motor axonal neuropathy (AMAN)**. AMAN is often associated with preceding *Campylobacter jejuni* infection and has prognostic/treatment implications (may recover more slowly than AIDP, but still responds to IVIG/plasma exchange).  \n\nMiller Fisher syndrome involves ophthalmoplegia, ataxia, and areflexia, which are absent here. Acute flaccid myelitis typically shows spinal cord MRI abnormalities and often asymmetric weakness.  \n\n**The answer is (B)**"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-005", "question": "A 47-year-old man with poorly controlled type 2 diabetes and daily alcohol use presents with 10 days of fever, right-sided headache, and progressive confusion. He was treated with oral amoxicillin-clavulanate for presumed sinusitis without improvement. On exam he is disoriented, febrile (38.8°C), with mild left hemiparesis and papilledema. CT head with contrast shows a 3.5-cm ring-enhancing lesion in the right frontal lobe with extensive surrounding edema contiguous with opacified frontal sinus. Emergent dexamethasone and broad-spectrum IV antibiotics are started. Neurocritical care team plans operative management. Which surgical approach is most appropriate now?", "options": ["CT-guided stereotactic needle aspiration of the abscess", "Open craniotomy with complete abscess excision and sinus drainage", "Endoscopic transnasal drainage of the frontal sinus only", "Placement of an external ventricular drain for CSF diversion and observation", "Delay surgical intervention; continue maximal medical therapy for 2 weeks"], "answer": "B", "answer_index": 1, "explanation": "A large frontal lobe abscess contiguous with frontal sinus and mass effect in an immunocompromised host favors open craniotomy with abscess excision plus definitive sinus drainage to eradicate the source and relieve mass effect. Needle aspiration alone risks persistent infection from ongoing sinus seeding; sinus drainage only is insufficient; EVD does not address the mass; delaying surgery risks herniation and neurological decline.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient has a large (3.5 cm) frontal lobe abscess with significant mass effect (papilledema, hemiparesis) and evidence of direct extension from an infected frontal sinus.  \nGiven the size, mass effect, failure of prior antibiotic therapy, and clear contiguous spread from the sinus, the definitive surgical management should address both the intracranial abscess and the source infection in the sinus.  \nStereotactic aspiration alone may not be sufficient given the size and associated sinus disease, and delaying surgery is unsafe due to mass effect and risk of herniation.  \nAn external ventricular drain would treat hydrocephalus but not the abscess itself.  \nEndoscopic sinus drainage alone would not address the intracranial abscess.  \nOpen craniotomy allows complete excision of the abscess, reduction of mass effect, and simultaneous drainage of the frontal sinus to eliminate the source.  \n\nThe answer is B"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-006", "question": "A 66-year-old man with COPD and metastatic non-small cell lung cancer (PD-L1 80%) started pembrolizumab 10 weeks ago. He presents with 4 days of worsening exertional dyspnea and dry cough, afebrile, with O2 saturation 90% on room air. CT pulmonary angiography shows no embolus but reveals new bilateral, patchy ground-glass opacities and reticular changes in the lower lobes with subpleural sparing. There is no infection on extensive workup, BNP is normal, and no cardiac ischemia. He is on no new drugs besides pembrolizumab. How should this complication be graded and managed now?", "options": ["Grade 1 pneumonitis; continue pembrolizumab with close monitoring only", "Grade 2 pneumonitis; hold pembrolizumab and start prednisone 0.5 mg/kg/day", "Grade 2 pneumonitis; hold pembrolizumab and start prednisone 1-2 mg/kg/day", "Grade 3 pneumonitis; permanently discontinue pembrolizumab and give IV methylprednisolone 1-2 mg/kg/day", "Grade 3 pneumonitis; permanently discontinue pembrolizumab and give infliximab immediately without steroids"], "answer": "C", "answer_index": 2, "explanation": "He has symptomatic but non-life-threatening immune-related pneumonitis (dyspnea, new infiltrates, no severe hypoxia), corresponding to grade 2; standard management is to hold the checkpoint inhibitor and start systemic steroids at 1-2 mg/kg/day with a prolonged taper. Grade 3 would involve severe symptoms or oxygen requirement; lower steroid doses or continuation of pembrolizumab are inadequate, and infliximab is reserved for steroid-refractory cases, not first-line.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The patient has pembrolizumab-related pneumonitis with new symptoms (exertional dyspnea, dry cough), hypoxemia to 90% on room air, and characteristic imaging findings.  \nAccording to CTCAE grading:  \n- Grade 2: Symptomatic, limiting instrumental ADL, medical intervention indicated, oxygen not indicated.  \n- Grade 3: Severe symptoms, limiting self-care ADL, oxygen indicated.  \n\nHere, O2 saturation is 90% on room air, indicating hypoxemia at rest, which typically qualifies as grade 3 (oxygen may be indicated). Management for grade 3 immune-mediated pneumonitis is permanent discontinuation of pembrolizumab and initiation of high-dose corticosteroids (e.g., IV methylprednisolone 1–2 mg/kg/day). Infliximab is reserved for steroid-refractory cases, not first-line.  \n\nThus, the best match is **D**.  \n\nThe answer is (D)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-007", "question": "A 9-year-old girl presents with 2 weeks of progressive headache, morning vomiting, and decline in school performance. Exam reveals papilledema, dysmetria, and truncal ataxia. MRI brain shows an enhancing midline posterior fossa mass infiltrating the cerebellar vermis and roof of the fourth ventricle, with obstructive hydrocephalus. After CSF diversion and near-total resection, histology shows small round blue cells with Homer-Wright rosettes. Molecular profiling reveals WNT-activated medulloblastoma, CTNNB1 mutation, and monosomy 6; no metastatic disease on staging. Which adjuvant treatment strategy is most appropriate?", "options": ["Craniospinal irradiation at standard dose plus multi-agent chemotherapy (high-risk protocol)", "Focal posterior fossa irradiation only plus maintenance oral temozolomide", "Reduced-dose craniospinal irradiation with posterior fossa boost plus chemotherapy (standard-risk protocol)", "Observation only after gross total resection due to favorable WNT subtype", "High-dose chemotherapy with autologous stem cell rescue, without craniospinal irradiation"], "answer": "C", "answer_index": 2, "explanation": "WNT-activated medulloblastoma in a child with non-metastatic disease and near-total resection is standard-risk; current practice uses reduced-dose craniospinal irradiation with posterior fossa boost plus multi-agent chemotherapy to maintain excellent survival while reducing late toxicity. Standard-dose/high-risk protocols are unnecessary; focal RT alone or observation is inadequate due to CSF dissemination risk; high-dose chemo without CSI is investigational and not standard in this scenario.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient has WNT-activated medulloblastoma (CTNNB1 mutation, monosomy 6), which is a favorable-risk molecular subtype.  \nShe is >3 years old, has no metastatic disease, and underwent near-total resection.  \nCurrent standard of care for WNT medulloblastoma in children is **reduced-dose craniospinal irradiation (CSI) with a boost to the tumor bed** (not the whole posterior fossa) plus chemotherapy, which is a standard-risk protocol adapted for the favorable biology.  \n\nOption C matches this approach.  \nOption A uses standard-dose CSI, which is excessive for WNT subtype.  \nOption B uses only focal radiation, which is insufficient.  \nOption D (observation only) is not standard even for WNT subtype.  \nOption E (high-dose chemo without CSI) is not appropriate for this case.  \n\nThe answer is C"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-008", "question": "A 71-year-old woman with hypertension and atrial fibrillation on rivaroxaban is admitted with sudden onset aphasia and right hemiplegia. CT head is negative for hemorrhage; CTA shows left M1 occlusion. Last rivaroxaban dose was 3 hours ago. Labs: creatinine 0.9 mg/dL, normal platelets, INR 1.2, anti-factor Xa level (rivaroxaban-calibrated) 170 ng/mL. She arrives 70 minutes after symptom onset. You are in a center with neurointerventional capability and access to andexanet alfa and 4-factor PCC. What is the best acute reperfusion strategy?", "options": ["Administer IV alteplase followed by mechanical thrombectomy", "Administer andexanet alfa to reverse rivaroxaban, then give IV alteplase", "Proceed directly to mechanical thrombectomy without IV thrombolysis", "Give 4-factor PCC then IV alteplase to offset rivaroxaban effect", "Defer reperfusion therapy and manage with permissive hypertension alone"], "answer": "C", "answer_index": 2, "explanation": "Recent rivaroxaban ingestion with high anti-factor Xa level is a contraindication to IV alteplase, and reversal with andexanet or PCC before tPA is not recommended due to uncertain safety and lack of evidence. In patients with large-vessel occlusion on DOACs, direct mechanical thrombectomy is the preferred reperfusion strategy. Withholding reperfusion altogether is inappropriate given eligibility for thrombectomy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient has a confirmed large vessel occlusion and is within the thrombolysis time window, but is on rivaroxaban with a therapeutic anti‑Xa level (170 ng/mL).  \nIV alteplase is contraindicated in patients on direct oral anticoagulants with a significant drug level.  \nReversal with andexanet alfa before thrombolysis is not an established protocol and could delay reperfusion.  \n4‑factor PCC is not reliably effective for rivaroxaban reversal in stroke and is not FDA‑approved for this purpose in the U.S.  \nGiven the presence of neurointerventional capability and a contraindication to alteplase, proceeding directly to mechanical thrombectomy is the most evidence‑based and guideline‑recommended approach.  \n\nThe answer is C"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-009", "question": "A 22-year-old man with sickle cell disease (HbSS) presents with high fever, cough, and pleuritic chest pain. CXR shows new multilobar infiltrates; oxygen saturation is 93% on 2 L/min nasal cannula. Labs: Hgb 7.2 g/dL (baseline 8.5), WBC 18,000/µL, platelets 310,000/µL, reticulocyte count 12%. He is diagnosed with acute chest syndrome and started on broad-spectrum antibiotics, incentive spirometry, and simple transfusion to Hgb 9.5 g/dL. Over 24 hours, oxygen requirement increases to 8 L/min with SpO2 90%, and CXR shows progression to near-complete bilateral airspace opacification. Hgb is now 10.3 g/dL, and he is tachypneic but not yet intubated. Which is the most appropriate next step?", "options": ["Increase simple transfusions to target Hgb 12 g/dL for better oxygen-carrying capacity", "Initiate exchange transfusion targeting HbS <30%", "Start high-dose corticosteroids to reduce pulmonary inflammation", "Add therapeutic anticoagulation for presumed pulmonary embolism", "Intubate and initiate low tidal-volume ventilation, deferring transfusion changes"], "answer": "B", "answer_index": 1, "explanation": "Worsening hypoxemia, radiographic progression, and clinical deterioration despite initial simple transfusion indicate severe acute chest syndrome, for which exchange transfusion to rapidly lower HbS (<30%) is recommended. Further simple transfusion risks hyperviscosity; steroids are controversial and may increase rebound pain; empiric anticoagulation is not first-line without PE evidence; ventilation may be needed but does not replace disease-modifying exchange.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This patient with sickle cell disease (HbSS) has acute chest syndrome (ACS) that is **progressing despite initial simple transfusion**, with worsening hypoxia and radiographic findings.  \nWhen ACS progresses or is severe despite initial management, and especially when oxygen requirements increase with near-complete bilateral opacities, guidelines recommend **exchange transfusion** to rapidly reduce the percentage of HbS (usually to <30%) to improve oxygen-carrying capacity and reduce sickling in the pulmonary vasculature.  \n\n**Why not other options:**  \n- **A** Simple transfusion to higher Hgb (e.g., 12 g/dL) increases viscosity and may worsen complications in ACS.  \n- **C** Steroids might be considered in some settings but carry risk of rebound vaso-occlusive crisis and are not first-line in rapidly progressive ACS with hypoxia.  \n- **D** Unsubstantiated without evidence of pulmonary embolism; anticoagulation not standard for ACS without proven thrombosis.  \n- **E** Intubation may be needed soon, but exchange transfusion should be initiated urgently first if he is not yet intubated, to potentially avoid mechanical ventilation or reduce its risks.  \n\nGiven the ongoing severe progression, **most appropriate next step** is urgent exchange transfusion.  \n\n**The answer is B**"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-010", "question": "A 58-year-old man with alcohol-related cirrhosis and portal hypertension is admitted with confusion and generalized tonic-clonic seizures. He has been on valproic acid for epilepsy for 5 years without prior complications. Medications include lactulose and spironolactone. Exam: asterixis, disorientation, jaundice, and mild ascites. Labs: Na 130 mmol/L, K 4.2 mmol/L, BUN 10 mg/dL, creatinine 0.7 mg/dL, AST 65 U/L, ALT 40 U/L, total bilirubin 3.8 mg/dL, INR 1.7, ammonia 96 µmol/L. Serum valproate level is therapeutic, but free valproate level is supratherapeutic; serum carnitine is low, and EEG shows triphasic waves without epileptiform activity. Which is the most appropriate antiseizure management strategy?", "options": ["Continue valproic acid but lower the dose and optimize lactulose therapy", "Discontinue valproic acid and start levetiracetam with IV L-carnitine supplementation", "Switch valproic acid to phenytoin with aggressive albumin replacement", "Add topiramate to valproic acid to improve seizure control", "Continue valproic acid and start rifaximin to reduce ammonia"], "answer": "B", "answer_index": 1, "explanation": "He has cirrhosis with hyperammonemic encephalopathy and high free valproate, consistent with valproate-induced hyperammonemic encephalopathy exacerbated by liver disease and carnitine deficiency; the best approach is to stop valproate, use a non-hepatically metabolized agent such as levetiracetam, and give IV L-carnitine. Dose reduction or adjuncts (lactulose, rifaximin) without discontinuing valproate will not adequately address toxicity; phenytoin is highly protein-bound and hepatically metabolized, and adding topiramate may worsen hyperammonemia.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient has cirrhosis with hepatic encephalopathy and seizures. Valproic acid can cause hyperammonemia and carnitine deficiency, especially in liver disease, and is associated with valproate-induced encephalopathy even with therapeutic total levels. The elevated ammonia, low carnitine, and supratherapeutic free valproate level point to valproate toxicity in this setting. The appropriate management is to discontinue valproic acid, replace it with a non‑hepatotoxic antiseizure medication (levetiracetam is preferred in liver disease), and give IV L‑carnitine to speed ammonia clearance and support metabolism.  \n\nThe answer is (B)"}]